Type 1 diabetes: how the first drug to delay its onset works on the NHS

England's National Health Service has made available the first drug capable of delaying the onset of type 1 diabetes. According to the BBC, the immunotherapy can give children and adults an average of three extra years before they need to start using insulin, provided it is given before the disease has fully developed.

Type 1 diabetes is an autoimmune condition in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Unlike type 2 diabetes, it is not linked to lifestyle and is most often diagnosed in childhood or young adulthood. As the cells are destroyed, the body can no longer regulate blood sugar and patients become dependent on insulin for life.

The new treatment aims to slow that immune attack. The drug works as an immunotherapy that dampens the activity of the immune cells, known as T cells, that damage the beta cells. By doing so, it postpones the destruction of those cells and allows the body to keep producing some of its own insulin for longer.

The drug is not a cure; it does not stop or reverse the disease. Instead, it delays the point at which the condition becomes clinically apparent. The average time gained, the BBC reports, is around three years — a meaningful window, especially for children, before daily insulin injections begin.

The treatment is aimed at people in an early stage of the disease. Doctors are targeting individuals who do not yet show symptoms but who carry the disease-specific autoantibodies in blood tests and have begun to show impaired sugar regulation. For the treatment to be effective, the disease therefore has to be identified very early.

Early diagnosis remains a challenge. Type 1 diabetes is often only diagnosed once symptoms — excessive thirst, frequent urination, weight loss and fatigue — become obvious. By that stage a significant proportion of the beta cells has already been lost and the window for delaying treatment has closed.

Experts say the drug's real potential will emerge alongside wider screening programmes. Screening at-risk children — for example those with a close relative who has type 1 diabetes — for autoantibodies could identify eligible individuals before symptoms appear.

The value of the time gained is not only practical. Delaying insulin therapy means young children and their families encounter the daily burdens of blood-sugar monitoring, injections and the risk of hypoglycaemia later. Preserving beta cells for longer can also make blood-sugar control easier in the later stages of the disease.

The treatment carries risks and side effects. Drugs that suppress the immune system can generally increase the risk of infection, and patients need to be closely monitored during treatment. Doctors weigh the time gained against possible side effects for each patient.

The NHS decision is seen as a sign that the direction of care in type 1 diabetes is shifting from managing the condition with insulin toward changing its course. Experts say that while the drug alone is not a revolution, it lays the groundwork for an approach that combines early diagnosis with immunotherapy.